One mission.

Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs.

Avalo announces positive top line data from LOTUS study in moderate to severe Hidradenitis Suppurativa (HS) Press release presentation

Avalo is a clinical-stage biotechnology company

fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Positive topline data was recently reported for our lead asset, abdakibart (AVTX-009), in a Phase 2 trial in hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs and advancing AVTX-010, a long-acting next-generation anti-IL-1β antibody.

Developing new medicines targeting the IL-1β pathway

Discover our innovative approach to next-generation treatments for inflammation.

Learn more

Our lead candidate, abdakibart (AVTX-009), recently completed Phase 2 clinical development

Explore how abdakibart (AVTX-009) could potentially transform the treatment of HS and other inflammatory diseases.

Learn more

Avalo is also advancing a long-acting next-generation anti-IL-1β monoclonal antibody (AVTX-010)

Discover how AVTX-010 has the potential to extend dosing intervals and build upon the differentiated profile established by abdakibart

Learn more

Join the passionate team at Avalo

Learn what makes us an inspiring and rewarding place to build your career.

Learn more